Description
辉瑞公司研发的新冠口服药，将新冠轻症、中度患者的住院或死亡风险降低约89%，并允许非专利制造向95个低收入和中等收入国家生产平价的新冠药物，预计会覆盖到53%的全球人口。从有效抗击新冠肺炎病毒的角度看，新冠疫苗和口服抗新冠药物的联合将建立起一道更加坚固的防线。
Audio
Featured in this Episode
No persons identified in this episode.
Transcription
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
0
upvotes
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
SpaceX Said to Pursue 2026 IPO
10 Dec 2025
Bloomberg Tech
Don’t Call It a Comeback
10 Dec 2025
Motley Fool Money
Japan Claims AGI, Pentagon Adopts Gemini, and MIT Designs New Medicines
10 Dec 2025
The Daily AI Show
Eric Larsen on the emergence and potential of AI in healthcare
10 Dec 2025
McKinsey on Healthcare
What it will take for AI to scale (energy, compute, talent)
10 Dec 2025
Azeem Azhar's Exponential View
Reducing Burnout and Boosting Revenue in ASCs
10 Dec 2025
Becker’s Healthcare -- Spine and Orthopedic Podcast